Adenocarcinoma/drug therapy; Carcinoma, Non-Small-Cell Lung/drug therapy; Hydroxychloroquine/therapeutic use; Lung Neoplasms/drug therapy; Sirolimus/analogs & derivatives; Adenocarcinoma/pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung/pathology; Enzyme Inhibitors/pharmacokinetics; Enzyme Inhibitors/therapeutic use; ErbB Receptors/antagonists & inhibitors; ErbB Receptors/genetics; Everolimus; Female; Follow-Up Studies; Humans; Hydroxychloroquine/pharmacokinetics; Immunosuppressive Agents/pharmacokinetics; Immunosuppressive Agents/therapeutic use; Lung Neoplasms/pathology; Male; Maximum Tolerated Dose; Middle Aged; Mutation/genetics; Neoplasm Staging; Prognosis; Sirolimus/pharmacokinetics; Sirolimus/therapeutic use; Tissue Distribution